Treatment of Clostridioides difficile Infection
For initial, non-severe CDI, fidaxomicin 200 mg twice daily for 10 days is the preferred first-line treatment, with vancomycin 125 mg four times daily for 10 days as an acceptable alternative; metronidazole should only be used when neither fidaxomicin nor vancomycin are available 1.
Initial CDI Episode
The treatment approach depends on disease severity:
Non-Severe CDI
- Preferred: Fidaxomicin 200 mg twice daily for 10 days 1
- Alternative: Vancomycin 125 mg four times daily for 10 days 1
- Last resort only: Metronidazole 500 mg three times daily for 10-14 days (only if fidaxomicin and vancomycin unavailable) 1
Non-severe disease is defined by WBC ≤15,000 cells/μL AND serum creatinine <1.5 mg/dL 1.
Severe CDI
The same agents are recommended (fidaxomicin preferred, vancomycin acceptable), but metronidazole is not appropriate even as an alternative 1. Recent guidelines have elevated fidaxomicin to first-line for both non-severe and severe disease based on superior efficacy in preventing recurrence 2, 3.
Fulminant CDI
For patients with hypotension/shock, ileus, or megacolon:
- Vancomycin 500 mg four times daily by mouth or nasogastric tube 1
- Add rectal vancomycin instillation if ileus present 1
- Add IV metronidazole 500 mg every 8 hours together with oral/rectal vancomycin, particularly with ileus 1
- ESCMID guidelines now endorse fidaxomicin and tigecycline as part of combination therapy for severe-complicated infection 2
Recurrent CDI
First Recurrence
- Preferred: Fidaxomicin 200 mg twice daily for 10 days, OR twice daily for 5 days followed by once every other day for 20 days 1
- Alternative: Vancomycin in tapered/pulsed regimen (125 mg four times daily for 10-14 days, then twice daily for 7 days, once daily for 7 days, then every 2-3 days for 2-8 weeks) 1
- Alternative: Standard vancomycin 125 mg four times daily for 10 days (especially if metronidazole was used initially) 1
Adjunctive therapy: Bezlotoxumab 10 mg/kg IV once during antibiotic administration can be added, particularly for patients at high risk of recurrence (age >65, immunocompromised, severe CDI) 1. However, use caution in patients with congestive heart failure 1.
Second or Subsequent Recurrence
- Fidaxomicin 200 mg twice daily for 10 days (or extended regimen) 1
- Vancomycin tapered/pulsed regimen 1
- Vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days 1
- Fecal microbiota transplantation (FMT) after at least 2 recurrences (3 total CDI episodes) 1
- Bezlotoxumab as adjunctive therapy 1
Key Clinical Considerations
Important shift in treatment paradigm: Metronidazole is no longer recommended when fidaxomicin or vancomycin are available 3. The emphasis has shifted from disease severity to risk of recurrence as the primary factor determining treatment strategy 3.
Access barriers are significant: A 2024 survey found that 82% of clinicians face challenges with outpatient insurance coverage for fidaxomicin, leading to vancomycin being the most frequently prescribed agent (83% of respondents) despite guideline recommendations 4. When fidaxomicin is not accessible due to cost or availability, vancomycin remains an appropriate and effective alternative 1.
Bezlotoxumab availability: While 74% of clinicians have access to bezlotoxumab, only 67% use it routinely 4. It should be strongly considered for patients with risk factors for recurrence, though data combined with fidaxomicin are limited 1.
FMT access: Traditional FMT using donor stool is available to only 48% of clinicians, while newer microbiome-based products have even more limited availability (36% for fecal microbiota live-jslm, 30% for fecal microbiota spores live-brpk) 4.